By proceeding, you agree to our Terms of Use and Privacy Policy.
In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference, we discuss tumor microenvironment modulation, improving delivery systems, novel approaches, and overcoming obstacles in IO. Join us for Cambridge Healthtech’s 2nd Annual Emerging Technologies for IO Targeting and Discovery conference. Here, experts and innovators come together to explore cutting-edge technologies and techniques for improving outcomes in the immuno-oncology space.
Explore the emerging tools and technologies for IO targeting and discovery.
Uncover more profound knowledge of tumor microenvironment modulation, improving delivery systems, novel approaches, overcoming obstacles in IO and many more.
Participate in interactive sessions and discussions to learn about Advances in Cellular Immunotherapies, Biotech Innovation in I-O and Cell Therapy and many more.
Immerse yourself in a stimulating environment where pioneering researchers ignite your inspiration and propel you to contribute to the fight against cancer.
Cambridge Healthtech Institute – Your Life Science Network Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients.
Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific.
BPS manufactures one of the largest selections of recombinant enzymes, neutralizing antibodies, inhibitor assay kits, lentiviruses and cell lines for drug discovery and continues to expand its drug discovery products.
Charles River Associates (CRA) is a global consulting firm specializing in litigation, regulatory, financial, and management consulting.
Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.
The CDMO segment of the world's leading biotech company GenScript.
The OmniAb discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.
Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.
Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal
Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibod
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in
BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.